

**PHD PROGRAM CYCLE XXX**

**ANNUAL REPORT**

**YEAR : 2014/2015**

**TITLE**

***“Impact of 719 Trp>Arg polymorphism of KIF 6 gene on coronary artery disease, contrast induced nephropathy and modulation of statin therapy effectiveness”.***

Student: Dr.ssa Lucia Barbieri

Tutor: Prof. Paolo Marino

During the first year of this PhD program I focused my research on the scientific project entitled: ***“Impact of 719 Trp>Arg polymorphism of KIF 6 gene on coronary artery disease, contrast induced nephropathy and modulation of statin therapy effectiveness”***.

Aim of this study is to assess the impact of Trp719Arg polymorphism on coronary artery disease (CAD), contrast induced nephropathy (CIN) development and on the modulation of the protective effects of statin among patients undergoing coronary angiography or percutaneous intervention (PCI).

We have included from July 2014 to August 2015 a total of 431 patients undergoing coronary angiography and/or PCI in our cath lab (AOU Maggiore della Carità, Novara). Informed consent was obtained in all patients before angiography. A blood sample for the determination of Trp719Arg polymorphism was collected for all patients. We therefore performed DNA extraction by the use of Sigma Aldrich Gen Elute system for each patient. We set the polymerase chain reaction (PCR) with reagents concentration optimization and MgCl<sub>2</sub> concentration curve. Amplification of the region of interest with polymerase chain reaction and consequent electrophoretic run on agarose gel and digestion with restriction enzyme Fok I was performed for each sample. Digestion product underwent another electrophoretic run on agarose gel and subsequent analysis with UV scan. We therefore were able to identify the different allelic patterns of our population.

These data are periodically collected in a dedicated database protected by password in which baseline clinical characteristics and angiographic and procedural characteristics are available for each patient.

In particular, serum creatinine and creatinine clearance (calculated by applying Cockcroft Gault formula) were collected at baseline, 24 and 48 hours after contrast exposure and the incidence of CIN (defined as an absolute increase of 0.5mg/dL or a relative increase of 25% of creatinin levels) was assessed among our population. Angiographic data were assessed by quantitative coronary angiography (QCA) analysis with “edge-detection system” (Siemens Acom Quantor QCA, Erlangen, Germany) by two experienced cardiologists who have no knowledge about the patients’ genetic profile. Significant coronary artery disease will be defined as a stenosis more than 70%, while borderline stenosis if between 30 and 70%.

The total number of patients that we aim to enroll during these 3 years is about 1500. We will subsequently perform a statistical analysis with SPSS 17.0 statistical package and we will assess the impact of Trp719 Arg KIF 6 polymorphism on coronary artery disease and on the modulation of the protective effects of statin treatment in this subgroup of patients. Moreover we will assess the impact of Trp719Arg polymorphism on the development of contrast induced nephropathy and on the modulation of the protective effects of statin treatment in this subgroup of patients.

**See in attachment publications, congress facts and seminars from May 2014 to date:**

## **Publications**

1. Schaffer A, Verdoia M, Barbieri L, Aprami TM, Suryapranata H, Marino P, Luca GD; on behalf of the Novara Atherosclerosis Study Group (NAS).” High-Density Lipoproteins and Coronary Artery Disease: A Single-Center Cohort Study”. *Angiology*. 2014 Sep;65(8):696-702.
2. Verdoia M, Secco GG, Barbieri L; Cassetti E, Schaffer A, Marino P, Suryapranata H, De Luca G on behalf of the Novara Atherosclerosis Study Group. “Platelet PIA1/PIA2 polymorphism and the risk of periprocedural myocardial infarction in patients undergoing elective PCI”. *Platelets*. 2014;25(5):367-72.

3. Verdoia M, Barbieri L, Schaffer A, Cassetti E, Marino P, Bellomo G, Sinigaglia F, De Luca G; Novara Atherosclerosis Study Group (NAS). Platelet-larger cell ratio and the risk of periprocedural myocardial infarction after percutaneous coronary revascularization. *Heart Vessels*. 2015 Jan;30(1):20-7.
4. Verdoia M, Schaffer A, Cassetti E, Barbieri L, Di Giovine G, Marino P, De Luca G; Novara Atherosclerosis Study Group (NAS). MTHFR polymorphism and risk of periprocedural myocardial infarction after coronary stenting. *Nutr Metab Cardiovasc Dis*. 2014 May;24(5):532-7.
5. Verdoia M, Schaffer A, Barbieri L, Cassetti E, Nardin M, Bellomo G, Marino P, Sinigaglia F, De Luca G; Novara Atherosclerosis Study (NAS) group. Diabetes, glucose control and mean platelet volume: a single-centre cohort study. *Diabetes Res Clin Pract*. 2014 May;104(2):288-94.
6. Verdoia M, Cassetti E, Schaffer A, Barbieri L, Giovine GD, Nardin M, Marino P, Sinigaglia F, Luca GD; NovaraAtherosclerosis Study Group (NAS). Relationship between glycoprotein IIIa platelet receptor gene polymorphism and coronary artery disease. *Angiology*. 2015 Jan;66(1):79-85.
7. Verdoia M, Barbieri L, Schaffer A, Cassetti E, Nardin M, Bellomo G, Aimaretti G, Marino P, Sinigaglia F, De Luca G; NovaraAtherosclerosis Study Group (NAS). Impact of diabetes on uric acid and its relationship with the extent of coronary artery disease and platelet aggregation: a single-centre cohort study. *Metabolism*. 2014 May;63(5):640-6.
8. Verdoia M, Schaffer A, Barbieri L, Cassetti E, Di Giovine G, Marino P, De Luca G; Novara Atherosclerosis Study Group (NAS). Homocysteine and risk of periprocedural myocardial infarction in patients undergoing coronary stenting. *J Cardiovasc Med (Hagerstown)*. 2015 Feb;16(2):100-5
9. Barbieri L, Verdoia M, Schaffer A, Nardin M, Marino P, De Luca G. The role of statins in the prevention of contrast induced nephropathy: a meta-analysis of 8 randomized trials. *J Thromb Thrombolysis*. 2014 Nov;38(4):493-502.
10. Verdoia M, Schaffer A, Cassetti E, Barbieri L, Di Ruocco MV, Perrone-Filardi P, Marino P, De Luca G; Novara Atherosclerosis Study Group (NAS). Glycosylated hemoglobin and coronary artery disease in patients without diabetes mellitus. *Am J Prev Med*. 2014 Jul;47(1):9-16.
11. Verdoia M, Schaffer A, Sartori C, Barbieri L, Cassetti E, Marino P, Galasso G, De Luca G. Vitamin D deficiency is independently associated with the extent of coronary artery disease. *Eur J Clin Invest*. 2014 Jul;44(7):634-42.
12. Verdoia M, Schaffer A, Barbieri L, Di Giovine G, Marino P, De Luca G; Novara Atherosclerosis Study Group (NAS). Uric acid and risk of periprocedural myocardial infarction in patients undergoing percutaneous coronary intervention. *Diabetes Metab Res Rev*. 2014 May;30(4):297-304.

13. Barbieri L, Verdoia M, Schaffer A, Niccoli G, Perrone-Filardi P, Bellomo G, Marino P, Suryapranata H, De Luca G. Elevated homocysteine and the risk of contrast-induced nephropathy: a cohort study. *Angiology*. 2015 Apr;66(4):333-8.
14. Verdoia M, Barbieri L, Schaffer A, Casetti E, Di Giovine G, Nardin M, Bellomo G, Marino P, De Luca G; Novara Atherosclerosis Study Group (NAS). Effect of diabetes mellitus on periprocedural myocardial infarction in patients undergoing coronary stent implantation. *Diabetes Metab Res Rev*. 2015 Jan;31(1):85-92.
15. Verdoia M, Schaffer A, Barbieri L, Sinigaglia F, Marino P, Suryapranata H, De Luca G; Novara Atherosclerosis Study Group (NAS). Eosinophils count and periprocedural myocardial infarction in patients undergoing percutaneous coronary interventions. *Atherosclerosis*. 2014 Sep;236(1):169-74.
16. Barbieri L, Verdoia M, Schaffer A, Casetti E, Marino P, Suryapranata H, De Luca G; Novara Atherosclerosis Study Group (NAS). Uric acid levels and the risk of Contrast Induced Nephropathy in patients undergoing coronary angiography or PCI. *Nutr Metab Cardiovasc Dis*. 2015 Feb;25(2):181-6.
17. Barbieri L, Verdoia M, Schaffer A, Casetti E, Di Giovine G, Marino P, Suryapranata H, De Luca G. Pre-diabetes and the risk of contrast induced nephropathy in patients undergoing coronary angiography or percutaneous intervention. *Diabetes Res Clin Pract*. 2014 Dec;106(3):458-64.
18. Verdoia M, Schaffer A, Barbieri L, Bellomo G, Marino P, Sinigaglia F, Suryapranata H, De Luca G; Novara Atherosclerosis Study (NAS) group. Impact of age on mean platelet volume and its relationship with coronary artery disease: a single-centre cohort study. *Exp Gerontol*. 2015 Feb;62:32-6.
19. Verdoia M, Schaffer A, Barbieri L, Aimaretti G, Marino P, Sinigaglia F, Suryapranata H, De Luca G; on behalf of the Novara Atherosclerosis Study Group (NAS). Impact of diabetes on neutrophil-to-lymphocyte ratio and its relationship to coronary artery disease. *Diabetes Metab*. 2015 Feb 2. pii: S1262-3636(15)00003-8. doi: 10.1016/j.diabet.2015.01.001. [Epub ahead of print]
20. Schaffer A, Verdoia M, Casetti E, Barbieri L, Perrone-Filardi P, Marino P, De Luca G. Impact of red blood cells count on the relationship between high density lipoproteins and the prevalence and extent of coronary artery disease: a single centre study. *J Thromb Thrombolysis*. 2015 Jul;40(1):69.
21. Verdoia M, Schaffer A, Pergolini P, Rolla R, Barbieri L, Bellomo G, Sinigaglia F, Marino P, Suryapranata H, De Luca G; on behalf of the Novara Atherosclerosis Study Group (NAS). Homocysteine levels influence platelet reactivity in coronary artery disease patients treated with acetylsalicylic acid. *J Cardiovasc Pharmacol*. 2015 Jul;66(1):35-40.

22. Verdoia M, Schaffer A, Barbieri L, Di Giovine G, Marino P, Suryapranata H, De Luca G; of the Novara Atherosclerosis Study Group (NAS). Glycosylated hemoglobin and the risk of periprocedural myocardial infarction in non-diabetic patients. *J Diabetes Complications*. 2015 May-Jun;29(4):517-22.
23. Verdoia M, Schaffer A, Barbieri L, Suryapranata H, De Luca G. Bivalirudin as compared to unfractionated heparin in patients undergoing percutaneous coronary revascularization: A meta-analysis of 22 randomized trials. *Thromb Res*. 2015 May;135(5):902-15.
24. Verdoia M, Schaffer A, Barbieri L, Di Giovine G, Marino P, Suryapranata H, De Luca G; Novara Atherosclerosis Study Group (NAS). Impact of gender difference on vitamin D status and its relationship with the extent of coronary artery disease. *Nutr Metab Cardiovasc Dis*. 2015 May;25(5):464-70.
25. Verdoia M, Barbieri L, Giovine GD, Marino P, Suryapranata H, De Luca G; Novara Atherosclerosis Study Group (NAS). Neutrophil to Lymphocyte Ratio and the Extent of Coronary Artery Disease: Results From a Large Cohort Study. *Angiology*. 2015 Mar 29. pii: 0003319715577529. [Epub ahead of print]
26. Barbieri L, Verdoia M, Schaffer A, Marino P, Suryapranata H, De Luca G; Novara Atherosclerosis Study Group (NAS). Impact of sex on uric acid levels and its relationship with the extent of coronary artery disease: A single-centre study. *Atherosclerosis*. 2015 Jul;241(1):241-8.
27. Verdoia M, Sartori C, Pergolini P, Nardin M, Rolla R, Barbieri L, Schaffer A, Marino P, Bellomo G, Suryapranata H, De Luca G; Novara Atherosclerosis Study Group (NAS). Prevalence and predictors of high-on treatment platelet reactivity with ticagrelor in ACS patients undergoing stent implantation. *Vascul Pharmacol*. 2015 May 6. pii: S1537-1891(15)00083-X. doi: 10.1016/j.vph.2015.04.014. [Epub ahead of print]
28. Barbieri L, Verdoia M, Schaffer A, Marino P, De Luca G. [Two catheters for one coronary perforation]. *G Ital Cardiol (Rome)*. 2015 Feb;16(2):112-5.
29. Verdoia M, Barbieri L, Suryapranata H, De Luca G. Switching from Clopidogrel to Prasugrel in patients undergoing PCI: A meta-analytic overview. *Platelets*. 2015 May 13:1-12. [Epub ahead of print]
30. Nardin M, Verdoia M, Sartori C, Pergolini P, Rolla R, Barbieri L, Schaffer A, Marino P, Bellomo G, Suryapranata H, De Luca G. Body Mass Index and platelet reactivity during dual antiplatelet therapy with clopidogrel or ticagrelor. *J Cardiovasc Pharmacol*. 2015 Jun 9. [Epub ahead of print]
31. Verdoia M, Pergolini P, Rolla R, Nardin M, Barbieri L, Schaffer A, Bellomo G, Marino P, Suryapranata H, De Luca G. Mean platelet volume and high-residual platelet reactivity in patients receiving dual antiplatelet therapy with clopidogrel or ticagrelor. *Expert Opin Pharmacother*. 2015 Aug;16(12):1739-47.

32. Verdoia M, Schaffer A, Barbieri L, Montalescot G, Collet JP, Colombo A, Suryapranata H, Luca G. Optimal Duration of Dual Antiplatelet Therapy After DES Implantation: A Meta-Analysis of 11 Randomized Trials. *Angiology*. 2015 Jun 11. pii: 0003319715586500. [Epub ahead of print]

33. Di Giovine G, Verdoia M, Barbieri L, Schaffer A, Aimaretti G, Bellomo G, Marino P, Suryapranata H, Sinigaglia F, De Luca G; Novara Atherosclerosis Study (NAS) group. Impact of diabetes on fibrinogen levels and its relationship with platelet reactivity and coronary artery disease: A single-centre study. *Diabetes Res Clin Pract*. 2015 May 18.

## Congress facts

1. Sulle Sponde del Ticino (emoclinic symposium) (May 2014)-**Partecipant**
2. EuroPCR 2014 **ORAL PRESENTATION** (May 2014): Barbieri L, Verdoia M, Schaffer A, Cassetti E, Di Giovine G, Marino P, De Luca G “Two catheters for one perforation”- Clinical case.
3. EuroPCR 2014-**ORAL PRESENTATION** (May 2014): Verdoia M, Schaffer A, Barbieri L, Cassetti E, Marino P, De Luca G “Benefits from new adenosine-diphosphate antagonists as compared to clopidogrel in patients with stable angina or acute coronary syndrome: a meta-analysis of randomised trials “.
4. Congresso GISE regionale (June 2014)-**Partecipant**
5. ESC congress 2014-**MODERATED POSTER SECTION** (August 2014) Barbieri L, Verdoia M, Schaffer A, Marino P, De Luca G. “Do statins prevent contrast induced nephropathy in patients undergoing coronary angiography or percutaneous intervention? A meta-analysis of 7 randomized trials”
6. ESC congress 2014-**MODERATED POSTER SECTION** (August 2014) Barbieri L, Verdoia M, Schaffer A, Cassetti E, Marino P, Suryapranata H, De Luca G.” Uric acid levels and the risk of contrast induced nephropathy in patients with impaired renal function undergoing coronary angiography or percutaneous intervention”
7. V International ACS cross road - **POSTER SECTION** (October 2014) Barbieri L, Verdoia M, Schaffer A, Cassetti E, Marino P, Suryapranata H, De Luca G.” Uric acid levels and the risk of contrast induced nephropathy in patients with impaired renal function undergoing coronary angiography or percutaneous intervention”.
8. V International ACS cross road - **POSTER SECTION** (October 2014) Barbieri L, Verdoia M, Schaffer A, Marino P, Suryapranata H, De Luca G. “Impact of gender on uric acid levels and its relationship with the extent of coronary artery disease: a single-centre cohort study”
9. V International ACS cross road (October 2014)– **Winner** of Young Interventionalist Competition: Clinical case “2 catheters for 1 perforation”
10. 35° Congresso nazionale Società Italiana di cardiologia Invasiva (GISE 2014)-**BEST POSTER SECTION** (October 2014): Barbieri L, Verdoia M, Schaffer A, Cassetti E, Marino P, Suryapranata H, De Luca G.” Uric acid levels and the risk of contrast induced nephropathy in patients with impaired renal function undergoing coronary angiography or percutaneous intervention”.



**11.** 35° Congresso nazionale Società Italiana di cardiologia Invasiva (GISE 2014)- POSTER SECTION (October 2014): Verdoia M, Barbieri L, Schaffer A, Di Giovine G, Cassetti E, Marino P, De Luca G “Impact of diabetes mellitus on periprocedural myocardial infarction in patients undergoing coronary stent implantation”

**12.** 35° Congresso nazionale Società Italiana di cardiologia Invasiva (GISE 2014)- ORAL PRESENTATION (October 2014) Barbieri L, Verdoia M, Schaffer A, Marino P, Suryapranata H, De Luca G. “Impact of gender on uric acid levels and its relationship with the extent of coronary artery disease: a single-centre cohort study”

**13.** 35° Congresso nazionale Società Italiana di cardiologia Invasiva (GISE 2014)- ORAL PRESENTATION (October 2014): Barbieri L “2 Catheters for 1 Perforation”

**14.** 35° Congresso nazionale Società Italiana di cardiologia Invasiva (GISE 2014)- ORAL PRESENTATION (October 2014) Verdoia M, Barbieri L, Schaffer A, Marino P, De Luca G. “Bivalirudin as compared to unfractionated heparin in patients undergoing percutaneous coronary revascularization: a meta-analysis of 16 randomized trials

**15.** 75° Congresso Nazionale della Società Italiana di Cardiologia (December 2014): Presentazione orale- Barbieri L, Verdoia M, Schaffer A, Nardin M, Marino P, De Luca G. “The role of Statins in the prevention of Contrast Induced Nephropathy: A Meta-analysis of 8 randomized trials”

**16.** 75° Congresso Nazionale della Società Italiana di Cardiologia (December 2014): Presentazione orale, sessione ICOT - Barbieri L. Clinical trials and tribulations: why so many logical ideas have failed?

**17.** 75° Congresso Nazionale della Società Italiana di Cardiologia (December 2014): Verdoia M, Barbieri L, Schaffer A, Di Giovine G, Nardin M, Marino P, De Luca G. “Impact of neutrophil to lymphocyte ratio on coronary artery disease and platelet aggregation among diabetic patients”

**18.** 75° Congresso Nazionale della Società Italiana di Cardiologia (December 2014): Poster session- Barbieri L, Verdoia M, Schaffer A, Marino P, Suryapranata H, De Luca G. “Impact of gender on uric acid levels and its relationship with the extent of coronary artery disease: a single center cohort study”

**19.** 75° Congresso Nazionale della Società Italiana di Cardiologia (December 2014): Poster session – Schaffer A, De Luca G, Verdoia M, Cassetti E, Barbieri L, Suryapranata H, Marino P. Relationship between homocysteine and coronary artery disease. Results from a large prospective cohort study.

**20.** American College 2015 (ACC Congress). Poster session- Barbieri L, Verdoia M, Marino P, Suryapranata H, De Luca G. “Contrast volume to Creatinine Clearance ratio for the prediction of Contrast Induced Nephropathy in patients undergoing coronary angiography or percutaneous intervention”

- 21. EuroPCR 2015- ORAL PRESENTATION (Maggio 2015):** Barbieri L, Verdoia M, Suryapranata H, Marino P, De Luca G. “Risk and benefits of a triple antithrombotic regimen in patients undergoing percutaneous coronary stent implantation requiring chronic oral anticoagulation: a meta-analysis of 12 trials”
- 22. EuroPCR 2015- ORAL PRESENTATION (Maggio 2015):** Barbieri L, Verdoia M, Schaffer A, Marino P, De Luca G. “You can lose everything...but not self-control!”
- 23. EuroPCR 2015- Poster session (Maggio 2015):** Barbieri L, Verdoia M, Marino P, Suryapranata H, De Luca G. “Contrast volume to Creatinine Clearance ratio for the prediction of Contrast Induced Nephropathy in patients undergoing coronary angiography or percutaneous intervention”
- 24. EuroPCR 2015- ORAL PRESENTATION (Maggio 2015):** Verdoia M, Schaffer A, Barbieri L, Nardin M, Marino P, Suryapranata H, De Luca G. “Advanced age and high-residual platelet reactivity in patients receiving dual antiplatelet therapy with clopidogrel or ticagrelor”
- 25. EuroPCR 2015- Presentazione orale (Maggio 2015):** Verdoia M, Barbieri L, Marino P, De Luca G The neverending dilemma of side-branch dissections .... When “patient “ decides
- 26. EuroPCR 2015- ORAL PRESENTATION (Maggio 2015):** Verdoia M, Nardin M, Barbieri L, Schaffer A, Sartori C, Marino P, Suryapranata H, De Luca G. “Diabetes mellitus, glucose control parameters and platelet reactivity in ticagrelor treated patients”
- 27. ESC 2015 – MODERATED POSTER PRESENTATION (August 2015):** Barbieri L, Verdoia M, Marino P, Suryapranata H, De Luca G. “Contrast volume to Creatinine Clearance ratio for the prediction of Contrast Induced Nephropathy in patients undergoing coronary angiography or percutaneous intervention”
- 28. ESC 2015 – MODERATED POSTER PRESENTATION (August 2015):** Verdoia M, Barbieri L, Schaffer A, Nardin M, Marino P, Suryapranata H, De Luca G. “ Advanced age and high-residual platelet reactivity in patients receiving dual antiplatelet therapy with clopidogrel or ticagrelor”
- 29. ESC 2015 – POSTER PRESENTATION (August 2015):** Barbieri L, Verdoia M, Marino P, Suryapranata H, De Luca G. “Risk and benefits of triple therapy in patients undergoing percutaneous coronary stent implantation requiring chronic oral anticoagulation: a meta-analysis of 12 trials”
- 30. ESC 2015 – POSTER PRESENTATION (August 2015):** Verdoia M, Nardin M, Barbieri L, Schaffer A, Marino P, Suryapranata H, De Luca G. “Diabetes mellitus, glucose control parameters and platelet reactivity in ticagrelor treated patients”

**31. ESC 2015 – POSTER PRESENTATION (August 2015):** Verdoia M, Nardin M, Barbieri L, Sartori S, Schaffer A, Di Giovine G, Marino P, Suryapranata H, De Luca G. “Vitamin D levels and high--residual platelet reactivity in patients receiving dual antiplatelet therapy with clopidogrel or ticagrelor”

**32. ESC 2015 – POSTER PRESENTATION (August 2015):** Di Giovine G, Verdoia M, Schaffer A, Barbieri L, Marino P, Suryapranata H, De Luca G. “Impact of age on fibrinogen levels and its relationship with coronary artery disease: a single center study”.

## Courses and Seminars

- July 14, 2014 Gene Therapy application (Prof Follenzi)
- The Borghese Sessions (Prof Steven R Ellis)
  - September 8, 2014 Skin as an organ; Layers of skin, cell types, developmental origins
  - September 9, 2014 Cell-Cell Interactions – anchoring junctions and occluding junctions, tight junctions
  - September 10, 2014 Cell Matrix Interactions – basal lamina; Epithelial-mesenchymal transition
  - September 11, 2014 Angiogenesis; Innervation
  - September 15, 2014 Basal layer stem cells, symmetric versus asymmetric divisions, transient amplifying cells; Solar radiation, nucleotide excision repair
  - September 16, 2014 Basal and squamous cell carcinomas; Melanoma – biology
  - September 17, 2014 Melanoma – treatment; Contact dermatitis
  - September 22, 2014 Other skin disorders, Other components of skin
- November 14, 2014 Dott. Boccafoschi "Tissue engineering: the state of the art"
- November 21, 2014 Prof. Prat "Stem cell in the regeneration and repair of the tissues and organs"
- December 4, 2014 Prof. Girish Patel "Uncovering the role of  $\beta$ -HPV in field cancerization: a collaboration in progress"
- December 16, 2014 Prof. Antonio Musarò "From the legend of Prometheus to regenerative medicine"
- January 19, 2015 Prof. Dr Yong-Sang Song "Anticancer strategy Targeting cancer cell metabolism in ovarian cancer"
- January 20, 2015 Dr Tonino Alonzi "Different molecular mechanisms regulate hepatocyte differentiation during the transitions between epithelial and mesenchymal states"
- January 21, 2015 Prof. Valeria Poli "Targeting the liver to cure myocarditis: a lesson from a model of STAT3-dependent auto-immune myocarditis"
- January 27, 2015 Prof. Antonio Sica "Myeloid cells as therapeutic target in cancer"
- April 9, 2015 Prof Zhong "Signal control in iNKT cell development and function"
- April 21, 2015 Prof. Percipalle "Actin-based mechanisms in the control of gene expression and cell fate"
- May 7, 2015 Prof John McDonald "An Integrated Approach to the Diagnosis and Treatment of Ovarian Cancer"
- May 25, 2015 Prof. Steve Ellis "Ribosomopathies"
- June 5, 2015 Dr Feltkamp "Recent Developments in (cutaneous) Human Polyomavirus Research"
- June 10, 2015 Prof Filigheddu "Basis of scientific research"
- July 28, 2015 Dott. Cantaluppi "Le cellule staminali nel danno renale acuto e nel trapianto di rene"